|
|||||
       |
Kevin Kit Parker (Harvard University) 7 March 2014. Biomedical engineers at Harvard University proposed a scheme for assessing the quality of stem cells used in drug testing to assure they transform into the cells and tissue they purport to represent. The team from Harvard’s Disease Biophysics Group, led by Kevin it Parker, published . . . → Read More: Quality Assurance Techniques Proposed for Stem Cells  Comments are closed  Regulations  biomedical, engineering, FDA, heart disease, life sciences, medical device, pharmaceuticals, standard, stem cells, university Project leaders Kam Leang, left, and Ben Rogers (University of Nevada, Reno) 6 March 2014. University of Nevada in Reno and NevadaNano, a spin-off company from the university, are developing an aerial robotic device for environmental sensing and reporting over a large area. The project is funded by a $150,000 Small Business Technology . . . → Read More: University, Spin-Off Partner on Enviro Flying Robotic Device Comments are closed Finance, Joint ventures/collaborations chemistry, computer science, DoD, engineering, entrepreneurs, grant, physical sciences, robotics, software, university Bag of altered T-cells for infusion (University of Pennsylvania) 6 March 2014. Researchers from University of Pennsylvania, Albert Einstein College of Medicine, and the biotechnology company Sangamo BioSciences showed the company’s gene-editing technology could engineer the immune cells of HIV-positive patients to resist infection and decrease their viral loads. Results of the early-stage . . . → Read More: Early Trial Shows Gene Editing Potential to Treat HIV/AIDS Comments are closed Joint ventures/collaborations, New products biomedical, biotechnology, clinical trials, genomics, HIV, life sciences, pharmaceuticals, university (butler.VA.gov) 5 March 2014. Life science and engineering researchers at Harvard University developed a sponge-like gel material that when seeded with embryonic cells in lab tests shrinks and hardens into a predecessor of human tooth tissue. The team led by Donald Ingber, director of Harvard’s Wyss Institute for Biologically Inspired Engineering, published its . . . → Read More: Bio-Gel Designed to Transform into Precursor Tooth Material Comments are closed New products biomedical, chemistry, engineering, life sciences, materials science, medical device, physical sciences, stem cells, university RNA illustration (Research.gov) 5 March 2014. RXi Pharmaceuticals Corp., a biotechnology company in Westborough, Massachusetts, received a patent for its technology based on RNA-interference to treat skin scars, including surgical scars. Patent number 8,664,189 was awarded yesterday by the U.S. Patent and Trademark Office to seven inventors and assigned to RXi Pharmaceuticals. RXi . . . → Read More: Patent Granted for RNA-Interference to Treat Scar Tissue Comments are closed Intellectual property biomedical, biotechnology, clinical trials, genomics, life sciences, patent, pharmaceuticals, USPTO (USDA.gov) 4 March 2014. A study by public health researchers at Harvard University shows children eating lunch at school increased their consumption of fruit and vegetables after new school lunch standards took effect. The team led by nutrition research fellow Juliana Cohen published its results online today in American Journal of Preventive Medicine. . . . → Read More: School Meal Standards Lead to More Fruit, Veggies Eaten (Paleontour/Flickr) 4 March 2014. Santen Pharmaceutical Co. in Osaka, Japan is licensing antibodies developed as a cancer therapy by Tracon Pharmaceuticals in San Diego as treatments for eye diseases. Tracon is expected to earn $10 million in an upfront payment from Santen, as well as undisclosed milestone payments and royalties. Tracon develops biologic . . . → Read More: Pharma Alliance Extends Cancer Antibodies to Eye Disorders Comments are closed Intellectual property, Joint ventures/collaborations Asia, biomedical, cancer, FDA, Japan, licensing, life sciences, pharmaceuticals (National Institute on Aging, NIH) Naurex Inc., a biotechnology company in Evanston, Illinois, says the U.S. Food and Drug Administration granted fast-track status for its drug candidate code-named GLYX-13 to treat depression. GLYX-13 is Naurex’s lead product for treatment of central nervous system disorders. The company develops drugs for diseases of the central . . . → Read More: FDA Fast-Tracks Depression Drug from Northwestern Spin-Off Comments are closed Regulations biomedical, biotechnology, clinical trials, entrepreneurs, FDA, life sciences, pharmaceuticals, university Lymphocyte (National Cancer Institute) 3 March 2014. Genocea Biosciences, a biotechnology company in Cambridge, Massachusetts, with Harvard Medical School and Dana-Farber Cancer Research Institute, are testing the company’s vaccine discovery platform to help target therapies for melanoma, an aggressive form of skin cancer. The collaboration is funded by Ludwig Institute for Cancer Research, . . . → Read More: Genocea, Harvard, Dana-Farber to Partner on Melanoma Comments are closed Joint ventures/collaborations biomedical, biotechnology, cancer, clinical trials, grant, life sciences, pharmaceuticals, university |
||||
|
Copyright © 2024 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |
|||||
RSS - Posts
You must be logged in to post a comment.